Docoh
Loading...

IPHA Innate Pharma

Innate Pharma SA is a biopharmaceutical company. It focuses on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. Its products include immunotherapy drugs and monoclonal antibodies. The Immunotherapy drugs are designated for cancer and inflammatory diseases. The Monoclonal antibodies targets receptors and pathways controlling the activation of innate immunity cells. The company was founded by Hervé Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié and François Romagné on September 15, 1999 and is headquartered in Marseille, France.

Company profile

IPHA stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

27 Apr 21
2 Dec 21
31 Dec 21
Quarter (USD)
Dec 20 Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

12.5% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 19 6 +216.7%
Opened positions 13 0 NEW
Closed positions 0 2 EXIT
Increased positions 2 0 NEW
Reduced positions 3 4 -25.0%
13F shares
Current Prev Q Change
Total value 44.94M 39.42M +14.0%
Total shares 9.9M 9.04M +9.4%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Bpifrance Participations 8.95M $39.12M 0.0%
Balyasny Asset Management 187.48K $1.16M NEW
BAC Bank Of America 174.1K $1.07M NEW
Affinity Asset Advisors 125K $771K NEW
VIRT Virtu Financial 109.57K $676K NEW
Optiver Holding B.V. 109.04K $673K +2326.9%
Pura Vida Investments 82.51K $509K NEW
Millennium Management 27.12K $167K -42.0%
Jane Street 24.43K $151K NEW
Cubist Systematic Strategies 20.13K $124K NEW
Largest transactions
Shares Bought/sold Change
Balyasny Asset Management 187.48K +187.48K NEW
BAC Bank Of America 174.1K +174.1K NEW
Affinity Asset Advisors 125K +125K NEW
VIRT Virtu Financial 109.57K +109.57K NEW
Optiver Holding B.V. 109.04K +104.55K +2326.9%
Pura Vida Investments 82.51K +82.51K NEW
Jane Street 24.43K +24.43K NEW
Cubist Systematic Strategies 20.13K +20.13K NEW
Millennium Management 27.12K -19.65K -42.0%
MS Morgan Stanley 17.73K -18.9K -51.6%
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg

Proxies

No filings